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Data on the relationship of antiretroviral exposure to meas-
ures of human immunodeficiency virus (HIV) persistence are 
limited. To address this gap, multiple viral, immunologic, and 
pharmacologic measures were analyzed from individuals with 
sustained virologic suppression on therapy (median 7  years) 
in the AIDS Clinical Trials Group A5321 cohort. Among 110 
participants on tenofovir-(TFV)-disoproxil-fumarate  (TDF)/
emtricitabine (FTC)-containing regimens, we found no sig-
nificant correlation between hair concentrations of individual 
antiretrovirals (ARVs) in the regimen and measures of HIV 
persistence (plasma HIV-1 RNA by single copy assay, cell-as-
sociated-DNA, cell-associated RNA) or soluble markers of in-
flammation. These findings suggest that higher systemic ARV 
exposure may not impact HIV persistence or inflammation.
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Among people living with human immunodeficiency virus 
(HIV) on treatment, strong relationships have been shown 
between systemic exposure to antiretroviral (ARV) therapy 
(ART) and virologic suppression in plasma (eg, HIV RNA < 40 
copies/mL) [1, 2]. Lower levels of ARVs in sanctuary sites 
may be associated with persistent HIV-1 replication on ART 
[3], although maintenance of the reservoir may be due to pro-
liferation of infected cells instead of ongoing replication [4]. 
Suboptimal ART adherence, even with suppression of viremia, 
has also been associated with higher levels of inflammation [5]. 
To date, however, studies have not examined the relationship 
between cumulative exposure to ARVs and measures of HIV-1 
persistence or inflammation.
Plasma levels measure short-term exposure to ARVs and are 
susceptible to day-to-day variation [6]. Cumulative measures of 
ARV exposure (such as drug levels in peripheral blood mono-
nuclear cells [PBMCs], dried blood spots, or hair) are increas-
ingly used to quantify exposure, whether in the context of HIV 
treatment or pre-exposure prophylaxis. Drug concentrations in 
hair reflect uptake from the systemic circulation over weeks to 
months [7], and can be used to measure cumulative exposure to 
all ARVs, regardless of whether they are activated intracellularly 
(such as nucleoside/nucleotide reverse transcriptase inhibitors 
[NRTIs]) or not (eg, non-NRTIs [NNRTIs], protease inhibitors 
[PIs], and integrase strand transfer inhibitors [INSTIs]).
Assays have been developed and validated to measure hair 
concentrations for a number of ARVs. Multiple studies have 
shown strong relationships between various ARV levels in hair 
and suppression of plasma viremia [1, 8]. The AIDS Clinical 
Trials Group (ACTG) HIV Reservoirs Cohort Study (A5321) 
collected multiple samples for measures of HIV-1 persistence, 
inflammation, and ARV exposure among participants with 
sustained suppression of plasma viremia [9]. We present here 
the first analysis examining the relationship between long-
term ARV exposure (using hair levels) and measurements of 




ACTG A5321 is a longitudinal cohort that includes participants 
who started ART during chronic HIV infection in the context of 
ACTG clinical trials, achieved HIV RNA levels <50 copies/mL 
after 6  months, and had documented sustained virologic sup-
pression with no documented breakthroughs [9]. Multiple viral, 
immunologic, and pharmacologic measures are collected pro-
spectively. The current analysis examines participants who were 
on tenofovir (TFV) disoproxil fumarate  (TDF)/emtricitabine 
(FTC)-based ART regimens at study entry. Participants provided 
written informed consent, with opt-in for hair collection, and 
ethics approval was obtained from all participating institutions.
Study Procedures
Hair Concentrations
Small samples of hair (approximately 50 strands) were cut from 
the scalp at the entry visit [1]. Hair concentrations of various 
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ARVs were measured via validated liquid chromatography/
tandem mass spectrometry-based methods in the University 
of California San Francisco Hair Analytical Laboratory. Our 
assays have been peer reviewed and approved by the Division of 
AIDS’ Clinical Pharmacology and Quality Assurance Program. 
Briefly, hair is cut into 1–2 mm length segments and 5 mg is 
weighed and processed. The ARV is extracted with an organic 
solvent, along with an internal standard, and then analyzed. For 
this analysis, ARV concentrations were measured in the 1.5 cm 
of hair closest to the participant’s scalp, representing approxi-
mately 6 weeks’ exposure.
Measures of HIV-1 Persistence
Residual low-level plasma viremia using a single copy assay 
(iSCA) was measured using real-time PCR with a probe for a 
highly conserved region of integrase in the HIV-1 pol gene [10]; 
the lower limit of quantification of this assay for a 4-mL plasma 
sample is 0.4 copies/milliliters (mL). Cell-associated RNA 
(CA-RNA) and cell-associated DNA (CA-DNA) were measured 
via published methods at the University of Pittsburgh ACTG 
Virology Specialty Laboratory [9].
Immunologic Measures
To evaluate levels of soluble biomarkers of inflammation and 
immune activation, frozen plasma samples from each partici-
pant were thawed and analyzed. Plasma concentrations of in-
terleukin (IL)-6, high-sensitivity CRP (hsCRP), soluble CD14 
(sCD14), soluble CD163 (sCD163), interferon gamma-induced 
protein (IP)-10, and tumor necrosis factor (TNF)-α were quan-
tified using enzyme-linked immunosorbent assay (ELISA) kits 
(R&D, Minneapolis, MN) at an ACTG Immunology Specialty 
Laboratory [9].
Statistical Analysis
Rank-based (Spearman) correlation coefficients assessed 
relationships between hair levels of ARVs (the average rank 
of TFV/FTC levels and concentrations of each individual 
drug) at study entry with HIV-1 persistence measurements 
(iSCA, CA-RNA, and CA-DNA) and soluble inflammatory 
markers. Hair levels, reservoir measures, and soluble bio-
markers were each assessed as continuous measures. For 
HIV-1 DNA values <3 and CA-RNA values <19 copies/106 
CD4+ T cells (below assay limits based on the number of cells 
analyzed), and iSCA <0.4 copies/mL, results were imputed to 
a lower number and analyzed as the lowest rank. The rela-
tionship between exposure reservoir measures was examined 
separately by sex. Differences in TFV concentrations with 
an accompanying pharmacoenhancer, cobicistat or ritona-
vir, in the regimen (versus an unboosted anchor ARV) were 
assessed by the Wilcoxon rank sum test; the rank sum test 
also evaluated differences in drug concentrations by iSCA 




Hair samples at A5321 entry were analyzed for 110 participants 
on TDF/FTC (Table  1); besides TDF/FTC, 49% were on an 
NNRTI, 25% on an INSTI, and 26% on a boosted PI. The median 
age of participants was 48 years (range 23–69) and 24% female. 
The distribution of self-reported race/ethnicity was 15% black, 
59% white, 23% Hispanic, and 3% Asian. The median duration 
on ART prior to entry was 7 years (range 4–16). Although all 
participants had sustained virologic suppression via commer-
cial HIV-1 RNA assays, 48% had residual low-level viremia 
(≥0.4 copies/mL) by iSCA. Median CA-DNA and CA-RNA lev-
els were 48 (interquartile range [IQR], 14–142) and 564 (IQR, 
229–1236) copies/106 CD4+ cells, respectively (Table 1).
Hair ARV Concentrations
Figure 1 shows the distribution of TFV and FTC hair concen-
trations among the 110 participants and the distribution of 
each anchor drug in hair for the subset of participants on each 
ARV. In participants with measureable TFV and FTC, concen-
trations varied over 100-fold. Concentrations of third agents 
were detectable in all participants and varied over a narrower 
range. Median concentrations of TFV in hair were 25% higher 
in participants on cobicistat or ritonavir than in those on an 
unboosted anchor (P = .015).
Table 1. Demographics of Participants in the A5321 Hair Study (n = 110)
Participant Characteristic N or Median (%, range or IQR)
Age at study entry (years) 48 (range 23–69)
Sex
 Male 84 (76%)
 Female 26 (24%)
Race/ethnicity
White non-Hispanic 65 (59%)
Black non-Hispanic 17 (15%)
 Hispanic 25 (23%)
Asian/Pacific Islander  3 (3%)
Years of ART at study entry 7 (range 4–16)
CD4+ cell count (cells/mm3)
 Pre-ART 250 (IQR, 101–359)
Study entry 661 (IQR, 494–839)
Pre-ART plasma HIV-1 RNA  
(log10cps/mL)
4.6 (IQR, 4.2–5.1)
ART regimen at A5321 entry  
(all TDF-FTC based)
46 (42%) EFV; 7 (6%) RPV; 1 (1%) NVP;  
11 (10%) ATV/r; 18 (16%) DRV/r; 5 (5%)  
EVG/cobi; 22 (20%) RAL
Measures of viral persistence
Plasma HIV-1 RNA (iSCA,  
copies/mL)
52% < 0.4; 48% ≥ 0.4
Cell associated HIV-1 RNA  
(copies/106 CD4+ cells)
48 (IQR, 14–142)
Cell associated HIV-1 DNA  
(copies/106 CD4+ cells)
564 (IQR, 229–1236)
Abbreviations: ART, antiretroviral therapy; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritona-
vir; EFV, efavirenz; EVG/cobi, elvitegravir/cobicistat;  IQR, interquartile range; iSCA, single 
copy assay; NVP, nevirapine; RPV, rilpivirine. 
Correlation Between Hair Concentrations of ARVs and HIV-1 Persistence
A significant correlation was not detected between TFV 
and FTC concentrations in hair and low-level viremia mea-
sured by iSCA (r = 0.09 and r = −0.04, respectively); results 
were comparable when examining iSCA <0.4 versus ≥0.4 cop-
ies/mL (P = .18 and P = .88 for TFV and FTC, respectively). 
Similarly, a significant correlation was not detected between 
rank-based TFV concentrations in hair and either CA-RNA 
(r = −0.02) or CA-DNA (r = −0.1), or between FTC concen-
trations in hair and either CA-RNA (r  =  0.01) or CA-DNA 
(r  =  −0.05). Finally, significant correlations were not found 
between hair concentrations of any of the NNRTI, PI, or 
INSTI (efavirenz, raltegravir, atazanavir, or darunavir) and 
the 3 measures of HIV-1 persistence (Supplementary Table 1). 
When stratifying analyses by sex, no significant correlations 
were observed between hair levels and HIV-1 persistence 
measures in either men or women.
Correlation Between Hair Concentrations of ARVs and Soluble Markers 
of Inflammation
Significant correlations were not detected between ranked TFV 
and FTC concentrations in hair and the 6 soluble biomarkers 
(Supplementary Table 2).
DISCUSSION
This is the first study to report the relationship between cumu-
lative measures of ARVs and measures of HIV-1 persistence or 
inflammation. We found no significant correlation among ARV 
hair levels and 3 different measures of HIV-1 persistence and 
6 soluble markers of inflammation in participants on suppres-
sive ART. We observed marked interindividual variability in 
ARV exposure, which has been reported previously [11], but 
not among individuals with sustained virologic suppression. 
Finally, we confirm previous findings [12] that concomitant 
pharmacoenhancers result in higher TFV levels.
Previous studies have examined the impact of ART intensi-
fication (adding agents to currently suppressive ART) on per-
sistent viremia and inflammation. In general, studies adding 
raltegravir and/or maraviroc to suppressive ART regimens early 
in HIV infection or in the context of chronic suppressive therapy 
[13, 14] have failed to show consistent or sustained impacts on 
markers of HIV-1 persistence. Similarly, in this cohort of indi-
viduals with sustained virologic suppression on ART at tradi-
tional doses, those exhibiting higher ARV concentrations in 
hair did not demonstrate lower measures of HIV persistence.
An ongoing debate has focused on whether low-level replica-
tion of HIV continues in tissues of individuals with suppression 
of viremia on ART. The fact that higher ARV concentrations in 
our study did not correlate with lower levels of viremia by iSCA 
(or lower levels of HIV transcription by CA-RNA) suggests that 
residual proviral transcripts and viremia are produced by stable 
reservoirs of infected cells that are not influenced by higher ex-
posure to ARVs. However, it is not known whether higher hair 
ARV concentrations are associated with higher local levels of 
ARVs in sanctuary sites, such as the lymph node, where on-
going replication has been postulated to occur. Previous stud-
ies have demonstrated that ARV concentrations in sanctuary 
sites (lymphatic tissues [3], genital tissues, the central nervous 
system [CNS]) are lower (when normalized by weight of tis-
sue or number of cells) than in the plasma. Ongoing work in 
A5321 will define the relationship between local concentrations 
of ARVs in various reservoir sites (CNS, genital tract, rectal tis-
sue) and local reservoir measures (eg, cell-associated RNA in 
the CNS) to help resolve this debate.
Of note was the wide interindividual variability in ARV hair 
concentrations seen among participants with sustained viro-
logic suppression (over 100-fold for TFV and FTC) (Figure 1), 
indicating that current ART regimens can be highly effective 
despite variable cumulative exposure. Such variability has 
been noted previously [11], but these studies were performed 
in cohorts with a range of virologic outcomes, whereas A5321 
participants had sustained, well-documented virologic sup-
pression. Prior studies have not observed variability in hair 
ARV levels by hair color or melaninization [14]. The variability 
in ARV levels seen among A5321 participants is likely due to 
interindividual variability in ARV pharmacokinetics, but also 
may reflect variability in adherence over the 6 weeks of expo-
sure measured by hair levels. A  prior study examined the as-
sociation between self-reported suboptimal adherence and a 
variety of soluble biomarkers of inflammation and immune ac-
tivation, finding an inverse relationship between adherence and 
some biomarkers [5]. Our analysis, which assessed actual drug 































Number of  Samples Contributed
110 110 31 10 12 1 15
DRV NVP RAL
Figure  1. Interindividual variability in antiretroviral (ARV) concentrations seen 
even among virologically suppressed individuals. ARV concentrations in hair below 
the lower limit of quantification were set to 0.001. Abbreviations: ATV, atazanavir; 
DRV, darunavir; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; RAL, raltegra-
vir; TFV, tenofovir. 
this highly selected population. Therefore, further study of the 
relationship between adherence, drug exposure, and inflamma-
tion is needed in a more routine clinic population, including 
examining correlates of poor adherence such as stress and sub-
stance use. Finally, as observed in previous analyses, cumulative 
TFV concentrations are higher when regimens are boosted with 
ritonavir or cobicistat than without pharmacoenhancement, a 
finding of increasing concern because higher ARV levels may 
lead to greater toxicity [12].
Our study has several limitations, including the small num-
bers of participants examined using individual ARVs other than 
FTC and TFV. In addition, at the time of the A5321 entry, the 
most commonly used INSTI was raltegravir, so data on either 
elvitegravir- or dolutegravir-based therapy is unavailable. In 
addition, the HIV persistence metrics were measured in periph-
eral samples (plasma and PBMCs) only. Because A5321 enrolled 
participants with sustained virologic suppression, we cannot 
assess whether drug levels are associated with HIV persistence 
in patients with more variable virologic outcomes. Finally, we 
did not collect data on self-reported adherence in A5321, which 
may have helped to elucidate some of the between-patient vari-
ability observed in hair concentrations.
In conclusion, we found no significant relationship be-
tween cumulative ARV exposure in chronically suppressed 
HIV-infected individuals on ART, as quantified by ARV con-
centrations in hair spanning a 100-fold range, and measures of 
either viral persistence or inflammation. This lack of correlation 
suggests that increasing exposure to currently available ARVs 
would not have a significant impact on HIV-1 persistence or in-
flammation. However, it is not known whether ARV concentra-
tions in hair adequately reflect ARV concentrations in tissues. 
Future studies need to investigate this question and the impact 
of higher systemic exposure to currently available INSTIs and 
newer ARVs on HIV persistence and inflammation. Such data 
are required to support future cure strategies focused on dis-
covering more potent ARV or ARV combinations, rather than 
approaches that reverse HIV-1 latency and promote the clear-
ance of stable reservoirs of HIV-infected cells [15].
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